Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Sources outlook
2.2.2. Derivatives outlook
2.2.3. End use outlook
2.3. Competitive Insights
Chapter 3. Australia Legal Cannabis Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Parent Market Outlook
3.3. Ancillary Market Outlook
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.2. Market restraint analysis
3.5. Australia Legal Cannabis Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Opportunity Analysis
3.7. Legal Cannabis Potential Trade Opportunity, Australia
3.7.1. Legal Marijuana Trade Route
3.7.2. Hemp Trade Route
3.8. Value Chain Analysis
3.8.1. Raw Material Trends
3.8.2. Manufacturing Trends
3.9. Australia Legal Cannabis User Pool
3.9.1. Estimated Number Of Cannabis Users In Australia, 2021-2025 (In Thousands)
3.10. Market Trends in the Country
3.10.1. Introduction of New Cannabis Products
3.10.2. Celebrity Cannabis Engagement
3.10.3. Growing Popularity of Craft and Boutique Cannabis Brands
3.10.4. Improved Cannabis Cultivation and Distribution Technology
3.10.5. Federal and State Cannabis Policy Opportunities
3.11. Regulatory Scenario in Australia
3.11.1. Overview
3.11.2. Cannabis Cultivation Norms
3.11.3. Ease Of Cannabis Business
3.11.4. Competitive Landscape
3.11.5. Regulatory Bodies Involved
3.11.6. Licensing Scenario
3.11.7. Market Penetration
3.12. Jurisdiction Analysis in Australia
3.12.1. Legal Framework & Division Of Powers
3.12.2. Federal Regulation Of Medicinal Cannabis
3.12.3. Access Pathways
3.12.4. State & Territory Implementation
3.12.5. Clinical & Regulatory Oversight
3.13. Cannabis Consumption Pattern Analysis, Australia
3.14. Legal Cannabis Potential Trade Opportunity, Australia
3.14.1. Global Legal Marijuana Trade Route
3.14.2. Global Hemp Trade Route
3.15. Legal Cannabis Seed to Shelf Story
3.15.1. Section Description
3.15.2. Cultivators & Growers
3.15.3. Manufacturers & Producers
3.15.4. Testers
3.15.5. Wholesalers & Distributors
3.15.6. Retailers
3.16. Supply Chain Analysis
3.16.1. Supply Chain Network from Hemp Cultivators to CBD Consumer Products
3.16.2. Supply Chain Network of Hemp Biomass to Industrial Applications
3.16.3. Supply Chain Network from Marijuana Plants to Marijuana Oil
3.17. Profit Margin Analysis
3.18. Import & Domestic Production Analysis
3.18.1. Product Volume Analysis - Imports Vs Domestic Production (2024/2025)
3.18.2. Estimated Average Cost Per Gram - Domestic Vs Imports (2024-2025)
Chapter 4. Australia Legal Cannabis Market: Sources Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Sources Segment Dashboard
4.3. Global Australia Legal Cannabis Market by Sources, 2021 to 2033
4.4. Marijuana
4.4.1. Marijuana market estimates and forecast 2021 to 2033 (USD Million)
4.4.2. Flower
4.4.2.1. Flower market estimates and forecast 2021 to 2033 (USD Million)
4.4.3. Oil and Tinctures
4.4.3.1. Oil and tinctures market estimates and forecast 2021 to 2033 (USD Million)
4.5. Hemp
4.5.1. Hemp market estimates and forecast 2021 to 2033 (USD Million)
4.5.2. Hemp CBD
4.5.2.1. Hemp CBD market estimates and forecast 2021 to 2033 (USD Million)
4.5.3. Supplements
4.5.3.1. Supplements market estimates and forecast 2021 to 2033 (USD Million)
4.5.4. Industrial Hemp
4.5.4.1. Industrial hemp market estimates and forecast 2021 to 2033 (USD Million)
Chapter 5. Australia Legal Cannabis Market: Derivatives Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Derivatives Segment Dashboard
5.3. Global Australia Legal Cannabis Market by Derivatives, 2021 to 2033
5.4. CBD
5.4.1. CBD market estimates and forecast 2021 to 2033 (USD Million)
5.5. THC
5.5.1. THC market estimates and forecast 2021 to 2033 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecast 2021 to 2033 (USD Million)
Chapter 6. Australia Legal Cannabis Market: End Use Estimates & Trend Analysis
6.1. Definitions and Scope
6.2. End Use Segment Dashboard
6.3. Australia Legal Cannabis Market by End Use, 2021 to 2033
6.4. Medical
6.4.1. Medical market estimates and forecast 2021 to 2033 (USD Million)
6.4.2. Cancer
6.4.2.1. Cancer market estimates and forecast 2021 to 2033 (USD Million)
6.4.3. Chronic Pain
6.4.3.1. Chronic pain market estimates and forecast 2021 to 2033 (USD Million)
6.4.4. Depression and Anxiety
6.4.4.1. Depression and anxiety market estimates and forecast 2021 to 2033 (USD Million)
6.4.5. Arthritis
6.4.5.1. Arthritis market estimates and forecast 2021 to 2033 (USD Million)
6.4.6. Diabetes
6.4.6.1. Diabetes market estimates and forecast 2021 to 2033 (USD Million)
6.4.7. Glaucoma
6.4.7.1. Glaucoma market estimates and forecast 2021 to 2033 (USD Million)
6.4.8. Migraines
6.4.8.1. Migraines market estimates and forecast 2021 to 2033 (USD Million)
6.4.9. Epilepsy
6.4.9.1. Epilepsy market estimates and forecast 2021 to 2033 (USD Million)
6.4.10. Multiple Sclerosis
6.4.10.1. Multiple sclerosis market estimates and forecast 2021 to 2033 (USD Million)
6.4.11. AIDS
6.4.11.1. AIDS market estimates and forecast 2021 to 2033 (USD Million)
6.4.12. Amyotrophic Lateral Sclerosis
6.4.12.1. Amyotrophic lateral sclerosis market estimates and forecast 2021 to 2033 (USD Million)
6.4.13. Alzheimer
6.4.13.1. Alzheimer market estimates and forecast 2021 to 2033 (USD Million)
6.4.14. Post Traumatic Stress Disorder (PTSD)
6.4.14.1. Post traumatic stress disorder market estimates and forecast 2021 to 2033 (USD Million)
6.4.15. Parkinson's Disease
6.4.15.1. Parkinson’s disease arket estimates and forecast 2021 to 2033 (USD Million)
6.4.16. Tourette
6.4.16.1. Tourette market estimates and forecast 2021 to 2033 (USD Million)
6.4.17. Others
6.4.17.1. Others market estimates and forecast 2021 to 2033 (USD Million)
6.5. Recreational
6.5.1. Recreational market estimates and forecast 2021 to 2033 (USD Million)
6.6. Industrial
6.6.1. Industrial market estimates and forecast 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles
7.4.1. Cann Group
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Zelira Therapeutics
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. AusCann Group Holdings Ltd
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Bod Science
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Althea Group
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Ecofibre
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Botanix SB Inc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. EPSILON
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Little Green Pharma
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Incannex Healthcare
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Vitura Health Limited
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Bioxyne
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. Green Farmers
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. ECS Botanics
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. Tasmanian Botanics
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
7.4.16. Cannatrek
7.4.16.1. Company overview
7.4.16.2. Financial performance
7.4.16.3. Product benchmarking
7.4.16.4. Strategic initiatives
7.4.17. Hale farms
7.4.17.1. Company overview
7.4.17.2. Financial performance
7.4.17.3. Product benchmarking
7.4.17.4. Strategic initiatives
7.4.18. Australian Natural Therapeutics Group
7.4.18.1. Company overview
7.4.18.2. Financial performance
7.4.18.3. Product benchmarking
7.4.18.4. Strategic initiatives
7.4.19. MedTEC Pharma
7.4.19.1. Company overview
7.4.19.2. Financial performance
7.4.19.3. Product benchmarking
7.4.19.4. Strategic initiatives
7.4.20. Aruma Labs
7.4.20.1. Company overview
7.4.20.2. Financial performance
7.4.20.3. Product benchmarking
7.4.20.4. Strategic initiatives
7.4.21. Montu Group
7.4.21.1. Company overview
7.4.21.2. Financial performance
7.4.21.3. Product benchmarking
7.4.21.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Australia legal cannabis market, by source, 2021-2033 (USD Million)
Table 4 Australia legal cannabis market, by derivatives, 2021-2033 (USD Million)
Table 5 Australia legal cannabis market, by end use, 2021-2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Australia legal cannabis market: market outlook
Figure 8 Australia legal cannabis competitive insights
Figure 9 Parent market outlook
Figure 10 Related/ancillary market outlook
Figure 11 Penetration and growth prospect mapping
Figure 12 Industry value chain analysis
Figure 13 Australia legal cannabis market driver impact
Figure 14 Australia legal cannabis market restraint impact
Figure 15 Porter’s Analysis
Figure 16 PESTLE Analysis
Figure 17 Australia legal cannabis market: Sources movement analysis
Figure 18 Australia legal cannabis market: Sources outlook and key takeaways
Figure 19 Marijuana market estimates and forecast, 2021-2033 (USD Million)
Figure 20 Flower market estimates and forecasts, 2021-2033 (USD Million)
Figure 21 Oil & tinctures market estimates and forecasts, 2021-2033 (USD Million)
Figure 22 Hemp market estimates and forecast, 2021-2033 (USD Million)
Figure 23 Hemp CBD market estimates and forecast, 2021-2033 (USD Million)
Figure 24 Supplements market estimates and forecast, 2021-2033 (USD Million)
Figure 25 Industrial hemp market estimates and forecast, 2021-2033 (USD Million)
Figure 26 Australia legal cannabis market: Derivatives movement analysis
Figure 27 Australia legal cannabis market: Derivatives outlook and key takeaways
Figure 28 CBD market estimates and forecast, 2021-2033 (USD Million)
Figure 29 THC market estimates and forecast, 2021-2033 (USD Million)
Figure 30 Others market estimates and forecast, 2021-2033 (USD Million)
Figure 31 Australia legal cannabis market: Derivatives movement analysis
Figure 32 Australia legal cannabis market: Derivatives outlook and key takeaways
Figure 33 Medical market estimates and forecast, 2021-2033 (USD Million)
Figure 34 Cancer market estimates and forecast, 2021-2033 (USD Million)
Figure 35 Chronic Pain market estimates and forecast, 2021-2033 (USD Million)
Figure 36 Depression and Anxiety market estimates and forecast, 2021-2033 (USD Million)
Figure 37 Arthritis market estimates and forecast, 2021-2033 (USD Million)
Figure 38 Diabetes market estimates and forecast, 2021-2033 (USD Million)
Figure 39 Glaucoma market estimates and forecast, 2021-2033 (USD Million)
Figure 40 Migraines market estimates and forecast, 2021-2033 (USD Million)
Figure 41 Epilepsy market estimates and forecast, 2021-2033 (USD Million)
Figure 42 Multiple Sclerosis market estimates and forecast, 2021-2033 (USD Million)
Figure 43 AIDS market estimates and forecast, 2021-2033 (USD Million)
Figure 44 Amyotrophic Lateral Sclerosis market estimates and forecast, 2021-2033 (USD Million)
Figure 45 Alzheimer market estimates and forecast, 2021-2033 (USD Million)
Figure 46 Post Traumatic Stress Disorder (PTSD) market estimates and forecast, 2021-2033 (USD Million)
Figure 47 Parkinson's Disease market estimates and forecast, 2021-2033 (USD Million)
Figure 48 Tourette market estimates and forecast, 2021-2033 (USD Million)
Figure 49 Others market estimates and forecast, 2021-2033 (USD Million)
Figure 50 Recreational market estimates and forecast, 2021-2033 (USD Million)
Figure 51 Industrial market estimates and forecast, 2021-2033 (USD Million)
Figure 52 Key company categorization
Figure 53 Heat map analysis, 2024
